Raynauds Disease - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Raynauds Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H1 2016', provides an overview of the Raynauds Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
- The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects
- The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Raynauds Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Raynauds Disease Overview 6
Therapeutics Development 7
Pipeline Products for Raynauds Disease - Overview 7
Raynauds Disease - Therapeutics under Development by Companies 8
Raynauds Disease - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Raynauds Disease - Products under Development by Companies 12
Raynauds Disease - Companies Involved in Therapeutics Development 13
Allergan Plc 13
Apricus Biosciences, Inc. 14
Bayer AG 15
Covis Pharmaceuticals, Inc. 16
Human Stem Cells Institute 17
Raynauds Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
acetylcysteine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
alprostadil - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ELS-140 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Neovasculgen - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
nitroglycerin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
onabotulinumtoxin A - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
riociguat - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Raynauds Disease - Recent Pipeline Updates 40
Raynauds Disease - Dormant Projects 54
Raynauds Disease - Discontinued Products 55
Raynauds Disease - Product Development Milestones 56
Featured News & Press Releases 56
Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference 56
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros 56
Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference 56
Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May 56
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 57
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon 57
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 58
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 59
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon 59
Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Raynauds Disease, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Raynauds Disease - Pipeline by Allergan Plc, H1 2016 13
Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H1 2016 14
Raynauds Disease - Pipeline by Bayer AG, H1 2016 15
Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H1 2016 16
Raynauds Disease - Pipeline by Human Stem Cells Institute, H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Raynauds Disease Therapeutics - Recent Pipeline Updates, H1 2016 40
Raynauds Disease - Dormant Projects, H1 2016 54
Raynauds Disease - Discontinued Products, H1 2016 55